Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Hepatocellular 54Stomach Neoplasms 42Carcinoma, Non-Small-Cell Lung 31Colorectal Neoplasms 21Esophageal Squamous Cell Carcinoma 15Nasopharyngeal Carcinoma 11Lung Neoplasms 11Rectal Neoplasms 10Esophageal Neoplasms 9Pancreatic Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Small Cell Lung Carcinoma 5Neoplasms 5Liver Neoplasms 5Cholangiocarcinoma 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Recurrence 4Neoplasm Metastasis 4Carcinoma, Renal Cell 4Lymphoma, Extranodal NK-T-Cell 3Colorectal Cancer Metastatic 3Colonic Neoplasms 3Carcinoma 3Breast Neoplasms 3Turcot syndrome 2Thyroid Neoplasms 2Spinocerebellar Degenerations 2Sarcoma 2Nonsquamous Non-Small Cell Lung Cancer 2

Interventions

Paclitaxel 7Doxorubicin 5pembrolizumab 4pazopanib 4Gemcitabine 4Bevacizumab 4durvalumab 3Radiotherapy 3Propranolol 3Docetaxel 3regorafenib 2cemiplimab 2Surveys and Questionnaires 2Sunitinib 2Standard of Care 2Nivolumab 2Ifosfamide 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1tremelimumab 1trebananib 1trastuzumab duocarmazine 1talimogene laherparepvec 1talazoparib 1spartalizumab 1sintilimab 1selinexor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hemangiosarcoma × sintilimab × Clear all
NCT05026736 2025-08-17

Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study

M.D. Anderson Cancer Center

Phase 2 Terminated
6 enrolled
Sarcoma

Hemangiosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡